Tumors overcome the action of the wasting factor ImpL2 by locally elevating Wnt/Wingless.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 34078667.
- Also identified by DOI 10.1073/pnas.2020120118 and PMC identifier 8201939.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Tumors often secrete wasting factors associated with atrophy and the degeneration of host tissues. If tumors were to be affected by the wasting factors, mechanisms allowing tumors to evade the adverse effects of the wasting factors must exist, and impairing such mechanisms may attenuate tumors. We use <i>Drosophila</i> midgut tumor models to show that tumors up-regulate Wingless (Wg) to oppose the growth-impeding effects caused by the wasting factor, ImpL2 (insulin-like growth factor binding protein [IGFBP]-related protein). Growth of Yorkie (Yki)-induced tumors is dependent on Wg while either elimination of <i>ImpL2</i> or elevation of insulin/insulin-like growth factor signaling in tumors revokes this dependency. Notably, Wg augmentation could be a general mechanism for supporting the growth of tumors with elevated ImpL2 and exploited to attenuate muscle degeneration during wasting. Our study elucidates the mechanism by which tumors negate the action of ImpL2 to uphold their growth during cachexia-like wasting and implies that targeting the Wnt/Wg pathway might be an efficient treatment strategy for cancers with elevated IGFBPs.
Medical subject headings
- Drosophila Proteins
- Insulin-Like Growth Factor Binding Proteins
- Neoplasm Proteins
- Neoplasms, Experimental
- Wnt Signaling Pathway
- Wnt1 Protein